![](https://entrepreneurs.utoronto.ca/wp-content/uploads/2022/07/COVIRASURGICAL_LOGO.ART_.jpg)
Covira Surgical
Covira develops drugs that work by modulating the biological activity of the gut microbiome to prevent diseases. Its platform technology generated a lead asset (CS-0003) that modulates bacterial virulence and restores microbial communities to prevent post-surgical infection. Covira’s approach is transformative to the field and the world is taking notice. In the 4th quarter of…